Transfection:Article Title: Vaccine molecules
Article Snippet: ELISA of Vaccine Proteins Vaccine plasmids were transiently transfected into HEK 293E cells by addition of 1 μg DNA and Lipofectamine (11668-019, Invitrogen, Life Technologies, CA, US), and supernatants assayed in ELISA as previously described (16). .. Briefly, 96 well-plates (Costar 3590, Sigma-Aldrich, MO, US) were coated with either anti human IgG (CH3 domain) (1 μg/ml) (MCA878G, AbD Serotec, CA, US) or NIP-BSA (1:1000), and vaccine proteins in transfected supernatants detected with biotinylated anti human IgG (CH3 domain) (HP6017, B3773-. .. 2ML, Sigma, MO, US) (1:3000) and alkaline phosphatase conjugated Streptavidin (RPN1234V, GE Healthcare, Buckinghamshire, UK) (1:3000).
Article Title: Vaccine molecules
Article Snippet: ELISA of Vaccine Proteins Vaccine plasmids were transiently transfected into HEK 293E cells by addition of 1 μg DNA and Lipofectamine (11668-019, Invitrogen, Life Technologies, CA, US), and supernatants assayed in ELISA as previously described (16). .. Briefly, 96 well-plates (Costar 3590, Sigma-Aldrich, MO, US) were coated with either anti human IgG (CH3 domain) (1 μg/ml) (MCA878G, AbD Serotec, CA, US) or NIP-BSA (1:1000), and vaccine proteins in transfected supernatants detected with biotinylated anti human IgG (CH3 domain) (HP6017, B3773-.2ML, Sigma, MO, US) (1:3000) and alkaline phosphatase conjugated Streptavidin (RPN1234V, GE Healthcare, Buckinghamshire, UK) (1:3000). .. The plates were developed using Phosfatase Substrate (P4744-10G, Sigma Aldrich, MO, US), and read with a Tecan reader (Tecan, Switzerland) using the Magellan version 5.03 program.
Generated:
Purification:
other:
Incubation:Article Title: Methods and compositions for treating staphylococcal infections
Article Snippet: .. Immune complexes were quantified following incubation with horseradish peroxidase (HRP)-conjugated human IgG (1:15,000, Bio-rad). ..
Binding Assay:Article Title: Methods and compositions comprising
Article Snippet: .. TABLE 6 The association constant for binding to human IgG of SpA variants Q9, 10K/S33X or Q9, 10K/G29X in combination with other amino acid substitutions# Parent SpA variant Parent SpA KA P with additional KA SD P varianta (×105 M−1)b SDc valued substitutionsa (×105 M−1)b (×105 M−1)c valuee SpAQ9, 10K/S33E 0.496 0.044 * SpAQ9, 10K/S33E/D36, 37A 0.568 0.1185 ns SpAQ9, 10K/S33E/G29A 1.265 0.6947 ns SpAQ9, 10K/S33E/D36, 37A/G29A 1.892 0.6793 ns SpAQ9, 10K/S33E/G29F 1.575 0.4060 ns SpAQ9, 10K/S33E/D36, 37A/G29F 14.850 13.480 *** SpAQ9, 10K/S33E/G29R 4.840 1.1960 ns SpAQ9, 10K/S33E/D36, 37A/G29R 10.240 5.2600 * SpAQ9, 10K/S33Q 4.068 2.835 ns SpAQ9, 10K/S33Q/D36, 37A 3.930 1.9290 ns SpAQ9, 10K/S33Q/G29A 2.563 1.3670 ns SpAQ9, 10K/S33Q/D36, 37A/G29A 4.893 3.8360 ns SpAQ9, 10K/S33Q/G29F 1.275 0.7355 ns SpAQ9, 10K/S33Q/D36, 37A/G29F 12.470 8.8810 * SpAQ9, 10K/S33Q/G29R 2.333 0.4245 ns SpAQ9, 10K/S33Q/D36, 37A/G29R 6.378 4.6820 ns SpAQ9, 10K/S33F 3.902 1.804 ns SpAQ9, 10K/S33F/D36, 37A 3.634 2.6420 ns SpAQ9, 10K/S33F/G29A 1.190 0.4299 ns SpAQ9, 10K/S33F/D36, 37A/G29A insoluble SpAQ9, 10K/S33F/G29F 2.440 0.7657 ns SpAQ9, 10K/S33F/D36, 37A/G29F insoluble SpAQ9, 10K/S33F/G29R 1.903 0.8693 ns SpAQ9, 10K/S33F/D36, 37A/G29R 9.056 4.9730 * SpAQ9, 10K/S33K 5.124 2.181 ns SpAQ9, 10K/S33K/D36, 37A 8.048 4.1050 ns SpAQ9, 10K/S33A 10.540 5.052 *** SpAQ9, 10K/S33A/D36, 37A 18.830 18.320 ns SpAQ9, 10K/G29F 3.460 1.586 ns SpAQ9, 10K/G29F/D36, 37A 3.723 1.5100 ns SpAQ9, 10K/G29R 6.056 0.981 ns SpAQ9, 10K/G29R/D36, 37A 6.808 3.6840 ns SpAQ9, 10K/G29A 11.310 3.119 ** SpAQ9, 10K/G29A/D36, 37A 1.78 0.5098 *** SpA-KR 5.464 0.767 ns SpARRVV 5.609 2.355 ns SpAKKAA 5.022 2.150 — aTest articles were immobilized on Bio-Rad ProteOn HTG Chip and subjected to Surface Plasmon Resonance measurements with increasing concentrations of human IgG and flowed over each Chip. ..
Variant Assay:Article Title: Methods and compositions comprising
Article Snippet: .. TABLE 6 The association constant for binding to human IgG of SpA variants Q9, 10K/S33X or Q9, 10K/G29X in combination with other amino acid substitutions# Parent SpA variant Parent SpA KA P with additional KA SD P varianta (×105 M−1)b SDc valued substitutionsa (×105 M−1)b (×105 M−1)c valuee SpAQ9, 10K/S33E 0.496 0.044 * SpAQ9, 10K/S33E/D36, 37A 0.568 0.1185 ns SpAQ9, 10K/S33E/G29A 1.265 0.6947 ns SpAQ9, 10K/S33E/D36, 37A/G29A 1.892 0.6793 ns SpAQ9, 10K/S33E/G29F 1.575 0.4060 ns SpAQ9, 10K/S33E/D36, 37A/G29F 14.850 13.480 *** SpAQ9, 10K/S33E/G29R 4.840 1.1960 ns SpAQ9, 10K/S33E/D36, 37A/G29R 10.240 5.2600 * SpAQ9, 10K/S33Q 4.068 2.835 ns SpAQ9, 10K/S33Q/D36, 37A 3.930 1.9290 ns SpAQ9, 10K/S33Q/G29A 2.563 1.3670 ns SpAQ9, 10K/S33Q/D36, 37A/G29A 4.893 3.8360 ns SpAQ9, 10K/S33Q/G29F 1.275 0.7355 ns SpAQ9, 10K/S33Q/D36, 37A/G29F 12.470 8.8810 * SpAQ9, 10K/S33Q/G29R 2.333 0.4245 ns SpAQ9, 10K/S33Q/D36, 37A/G29R 6.378 4.6820 ns SpAQ9, 10K/S33F 3.902 1.804 ns SpAQ9, 10K/S33F/D36, 37A 3.634 2.6420 ns SpAQ9, 10K/S33F/G29A 1.190 0.4299 ns SpAQ9, 10K/S33F/D36, 37A/G29A insoluble SpAQ9, 10K/S33F/G29F 2.440 0.7657 ns SpAQ9, 10K/S33F/D36, 37A/G29F insoluble SpAQ9, 10K/S33F/G29R 1.903 0.8693 ns SpAQ9, 10K/S33F/D36, 37A/G29R 9.056 4.9730 * SpAQ9, 10K/S33K 5.124 2.181 ns SpAQ9, 10K/S33K/D36, 37A 8.048 4.1050 ns SpAQ9, 10K/S33A 10.540 5.052 *** SpAQ9, 10K/S33A/D36, 37A 18.830 18.320 ns SpAQ9, 10K/G29F 3.460 1.586 ns SpAQ9, 10K/G29F/D36, 37A 3.723 1.5100 ns SpAQ9, 10K/G29R 6.056 0.981 ns SpAQ9, 10K/G29R/D36, 37A 6.808 3.6840 ns SpAQ9, 10K/G29A 11.310 3.119 ** SpAQ9, 10K/G29A/D36, 37A 1.78 0.5098 *** SpA-KR 5.464 0.767 ns SpARRVV 5.609 2.355 ns SpAKKAA 5.022 2.150 — aTest articles were immobilized on Bio-Rad ProteOn HTG Chip and subjected to Surface Plasmon Resonance measurements with increasing concentrations of human IgG and flowed over each Chip. ..
SPR Assay:Article Title: Methods and compositions comprising
Article Snippet: .. TABLE 6 The association constant for binding to human IgG of SpA variants Q9, 10K/S33X or Q9, 10K/G29X in combination with other amino acid substitutions# Parent SpA variant Parent SpA KA P with additional KA SD P varianta (×105 M−1)b SDc valued substitutionsa (×105 M−1)b (×105 M−1)c valuee SpAQ9, 10K/S33E 0.496 0.044 * SpAQ9, 10K/S33E/D36, 37A 0.568 0.1185 ns SpAQ9, 10K/S33E/G29A 1.265 0.6947 ns SpAQ9, 10K/S33E/D36, 37A/G29A 1.892 0.6793 ns SpAQ9, 10K/S33E/G29F 1.575 0.4060 ns SpAQ9, 10K/S33E/D36, 37A/G29F 14.850 13.480 *** SpAQ9, 10K/S33E/G29R 4.840 1.1960 ns SpAQ9, 10K/S33E/D36, 37A/G29R 10.240 5.2600 * SpAQ9, 10K/S33Q 4.068 2.835 ns SpAQ9, 10K/S33Q/D36, 37A 3.930 1.9290 ns SpAQ9, 10K/S33Q/G29A 2.563 1.3670 ns SpAQ9, 10K/S33Q/D36, 37A/G29A 4.893 3.8360 ns SpAQ9, 10K/S33Q/G29F 1.275 0.7355 ns SpAQ9, 10K/S33Q/D36, 37A/G29F 12.470 8.8810 * SpAQ9, 10K/S33Q/G29R 2.333 0.4245 ns SpAQ9, 10K/S33Q/D36, 37A/G29R 6.378 4.6820 ns SpAQ9, 10K/S33F 3.902 1.804 ns SpAQ9, 10K/S33F/D36, 37A 3.634 2.6420 ns SpAQ9, 10K/S33F/G29A 1.190 0.4299 ns SpAQ9, 10K/S33F/D36, 37A/G29A insoluble SpAQ9, 10K/S33F/G29F 2.440 0.7657 ns SpAQ9, 10K/S33F/D36, 37A/G29F insoluble SpAQ9, 10K/S33F/G29R 1.903 0.8693 ns SpAQ9, 10K/S33F/D36, 37A/G29R 9.056 4.9730 * SpAQ9, 10K/S33K 5.124 2.181 ns SpAQ9, 10K/S33K/D36, 37A 8.048 4.1050 ns SpAQ9, 10K/S33A 10.540 5.052 *** SpAQ9, 10K/S33A/D36, 37A 18.830 18.320 ns SpAQ9, 10K/G29F 3.460 1.586 ns SpAQ9, 10K/G29F/D36, 37A 3.723 1.5100 ns SpAQ9, 10K/G29R 6.056 0.981 ns SpAQ9, 10K/G29R/D36, 37A 6.808 3.6840 ns SpAQ9, 10K/G29A 11.310 3.119 ** SpAQ9, 10K/G29A/D36, 37A 1.78 0.5098 *** SpA-KR 5.464 0.767 ns SpARRVV 5.609 2.355 ns SpAKKAA 5.022 2.150 — aTest articles were immobilized on Bio-Rad ProteOn HTG Chip and subjected to Surface Plasmon Resonance measurements with increasing concentrations of human IgG and flowed over each Chip. ..
|